**Looking Ahead to Fall 2024 🍁 Life Science Events**

Fall is not just the season of football, cooling temperatures, and everything Pumpkin Spice-related. It is a time of discovery in the Life Science and MedTech world. Conferences like [MedTechX](https://www.terrapinn.com/conference/biotechxusa/index.stm), [ARS 2024](https://www.american-rhinologic.org/2024-annual-meeting), [HLTH](https://www.hlth.com/2024event), [DIA Real-World Evidence](https://www.diaglobal.org/en/conference-listing/meetings/2024/10/real-world-evidence-conference), and [ISPOR Europe](https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2024) draw the brightest minds – researchers, data scientists, informaticists, market access experts, and medical affairs teams – eager to explore the cutting-edge technologies that will revolutionize the way we develop, launch, and monitor therapies.

At Latica, we’re particularly excited about the role Artificial Intelligence (AI) and Large Language Models (LLMs) are playing in this transformative journey. These technologies are fueling significant advancements in real-world data analysis, a crucial aspect of drug development and post-market surveillance.

Here’s what we at Latica are excited about:

- **Poster Presentations:** Partnering with industry leaders, we’ll be showcasing insightful research based on real-world data that has only recently been available via Latica Technology.
- **Real-World Data Research Collaboration:** We’re looking forward to collaborating with partners to define innovative research projects for 2025 that leverage Latica’s extensive RWD dataset. Our platform and partnerships create a unique data resource powered by over 175 million real-world patient encounters and millions of valuable unstructured data points, providing a powerful platform for groundbreaking discoveries.

**Ready to Leverage Real-World Data for Success?**

Latica offers a comprehensive solution for harnessing the power of real-world data.

Connect with us on [LinkedIn](http://linkedin.com/in/collin-labar) or use the [Contact Us](/content/life-sciences/index.html) link to learn more about how to achieve breakthrough results and develop impactful research for future events.

**Don’t miss the opportunity to revolutionize your approach to medical activities, drug development, and market access this fall!** 🍁🍂🎃 🏈

**The Shared Language of Immunology**

People with seemingly unrelated diseases can have similar experiences because of one common factor: excessive type 2 inflammation, which in itself is part of a normal immune response to allergens and infections. However, when it goes into overdrive, it can contribute to inflammatory diseases such as [asthma](https://www.sanofi.com/en/magazine/our-science/taking-down-type-2-inflammatory-disease), atopic dermatitis (eczema), chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (a chronic and progressive digestive disease), or even certain environmental allergies. Treatments directed at certain interleukins (ie. IL-12, IL-23 etc) work in a variety of disease states including:

- Asthma
- Atopic Dermatitis (AD)
- Nasal Polyps (NP), or Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
- Eosinophilic Esophagitis (EoE)
- Prurigo Nodularis (PN)
- Certain Food Allergies

From a real-world data (RWD) perspective, large data sets plus predictive analytics and machine learning should enable crucial insights. The correct drug at the right time and dose for each patient, and evaluation of response and natural history in people with more than one disease (ie. eosinophilic esophagitis and asthma).

Large data sets have already provided insights into the natural history of CRSwNP, selection and dosing of biologics in different patient populations in IBD. Using LLMs, images, and videos, along with longitudinal real-world data will provide increased understanding of multiple inflammatory and immunologic diseases.

**Explore Real-World Data With Latica**

Explore how Latica’s AI-powered platform can revolutionize your approach to life science research with domain expertise in gastroenterology, otolaryngology, dermatology, and more.

**About the Author**

Dr. [Robert Eisdorfer](mailto:robert@lynx.md), Chief Medical Officer and co-founder of Latica is a Gastroenterology Specialist with over 38 years of experience in the medical field. He is passionate about advancing medicine and improving patient outcomes through the application of meaningful medical research and technology. Dr. Eisdorfer works with healthcare organizations around the world to provide strategic guidance for the consideration and adoption of new technology solutions.

**Overcoming the Challenges of Traditional Data**

As a bioinformatics data scientist, I’ve spent years in the trenches of medical research. One of them was working at a small startup that aimed to find the best treatments for cancer based on biopsy results. In that role, the process was meticulous and slow—each study required us to carefully design a protocol, recruit patients with specific indications, and wait for months to determine whether the treatment was effective. We collected data painstakingly, one patient at a time, over long periods. This is still the case for many diagnostic startups and even large pharmaceutical companies, where every new patient adds a valuable data point, but progress is often measured in small, incremental steps.

**A Paradigm Shift: The Power of Pre-Existing Data**

When I moved to my new role, the first thing that blew my mind was the sheer volume and accessibility of the data. All the information we had slowly accumulated in my previous job—biopsy images, treatment plans, patient responses—was already here, waiting to be analyzed. And not just for a few patients, but for thousands, across a wide range of indications. It felt like stepping into a researcher’s dream.

While retrospective data should never fully replace the rigor of prospective data, the ability to rapidly generate and test new hypotheses using pre-existing data is a game-changer. Instead of waiting for months or years to gather enough data to draw meaningful conclusions, I can now leverage vast datasets that span different providers, countries, indications, and populations. The potential to validate findings across multiple datasets, in a fraction of the time it would take in a traditional research setting, is nothing short of revolutionary.

**The Impact on Medical Research**

This transition has opened my eyes to the incredible possibilities that come with having access to such rich, diverse datasets. Here are just a few ways in which this data is transforming the research landscape:

1. **Accelerating Hypothesis Generation and Testing:** In the traditional research model, formulating and testing a hypothesis could take years. With the data now at our disposal, hypotheses can be generated and tested almost as quickly as we can code. This rapid iteration process allows us to explore a wide array of potential treatments and diagnostic markers, refining our understanding at an unprecedented pace.
2. **Enhancing the Power of Retrospective Analysis:** While prospective studies remain the gold standard, retrospective analysis using large datasets offers a powerful complement. By analyzing existing data, we can identify patterns and correlations that might not be apparent in smaller studies. Finding new biomarkers that were not even collected in traditional studies. This can inform the design of future prospective studies, making them more focused and effective.
3. **Validating Across Diverse Populations:** One of the biggest challenges in medical research is ensuring that findings are applicable across different populations and centers. With access to data from multiple providers and countries, we can validate our hypotheses in diverse patient populations. This not only increases the robustness of our findings but also ensures that treatments are more universally effective.
4. **Streamlining Phase 4 Clinical Studies:** Traditionally, Phase 4 clinical studies, which assess the long-term side effects of new drugs, are lengthy and resource-intensive. By leveraging existing data, we can conduct these studies more efficiently, monitoring patient outcomes over extended periods and identifying long-term adverse effects more quickly and without opening a new study, only by analyzing the data that is collected anyway in the clinics.

**Challenges and Opportunities**

Of course, there are many challenges that come with working with such vast datasets. Data quality, integration across different sources, and ensuring patient privacy are just a few of the hurdles we face. However, these challenges are far outweighed by the opportunities. Having access to this data is the dream of any researcher, offering a chance to make meaningful discoveries that can transform patient care.

**The Dream of Every Researcher** Reflecting on my journey from a small startup to my current role, I can’t help but feel a sense of excitement and possibility. The transition has not only expanded my access to data but has also broadened my perspective on what’s possible in medical research. The ability to work with such a rich, diverse dataset is something I could only dream of in my previous roles, and I am eager to see how this data will continue to drive innovation and improve patient outcomes in the years to come.

**About the Author**

In addition to her work with Latica, Yael is also the Director of Computational Biology at Point6 Bio, where she has been leading research since March 2024. With over a decade of experience in data science and bioinformatics, Yael has held senior roles at Pyxis Diagnostics, including VP of Data Science, and at BiomX Ltd, where she served as Head of Data Science. Her expertise spans big data analytics, computational biology, and bioinformatics, honed through her academic journey at Tel Aviv University, where she earned a PhD in Bioinformatics.

**Unlocking the Power of Real-World Data for Strategic Initiatives**

For years, fragmented healthcare data systems and privacy concerns hampered efforts to use real-world data for strategic initiatives. Latica’s platform bridges this gap. By providing a secure and controlled environment for anonymized data sharing, [Latica empowers healthcare providers](/content/healthcare-providers/index.html) to:

- **Fuel Medical Research and Development:** The Kineret Project exemplifies this. Latica integrates with a vast database of patient information, allowing researchers to mine valuable insights for developing new treatments and improving healthcare delivery.
- **Enhance Population Health Management:** Clalit Health Services, through its partnership with Latica, can leverage real-world data to identify at-risk populations and tailor preventive care programs. This proactive approach improves overall population health outcomes.
- **Optimize Clinical Decision-Making:** Access to anonymized patient data through Latica empowers clinicians to make data-driven decisions at the point of care, potentially leading to better treatment plans and improved patient outcomes.

**Measurable Results: A Win for All**

The partnerships between Latica and the Israeli healthcare providers have yielded demonstrably positive results. Both Clalit Health Services and the Government Medical Centers Division have leveraged the platform to:

- **Increase Internal Research Projects:** The secure and user-friendly platform has streamlined internal research efforts, enabling healthcare providers to initiate and complete a significantly higher number of in-house research projects.
- **Scale Up External Research Partnerships:** Latica has facilitated a dramatic increase in the number of external research partnerships for both providers. The platform allows both provider organizations to securely partner with life science and academic researchers to securely access anonymized data, accelerating collaboration and innovation.

**Secure Real-World Data Sharing: A Key to Success**

The foundation of these successful partnerships lies in Latica’s secure real-world data sharing capabilities.

- **Data Anonymization:** Patient privacy remains paramount. In the case of Kineret and Clalit, they are taking the lead on all de-identification of data before granting permissioned researchers to work with the data. For other Latica partners, the Latica platform ensures sensitive data is anonymized before being accessed protecting patient identities while enabling valuable research and analysis.
- **Granular Access Control:** Healthcare providers retain complete control over their data. The Latica platform allows the provider organization to grant granular access permissions to researchers and institutions, ensuring data is used only for approved purposes.
- **Robust Security Protocols:** Latica adheres to the strictest security protocols, safeguarding sensitive healthcare data and ensuring compliance with regulations.

**A Bright Future for Healthcare**

The collaborations between Latica, the Israeli Ministry of Health, and Clalit Health Services create opportunities to advance healthcare discovery informed by real-world data. By addressing strategic data initiatives and leveraging secure real-world data sharing, these partnerships pave the way for a future filled with groundbreaking discoveries, improved population health management, and ultimately, better patient outcomes.